AN2 Therapeutics Inc (ANTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $172.64M
Last updated: Nov 17, 2026 at 4:10 PM ET
AN2 Therapeutics Inc (ANTX) Statistics
AN2 Therapeutics (ANTX) has a market cap of $172.64M and an enterprise value of $152.44M. Its share count is up 52.31% from a year earlier. It holds $20.21M more cash than debt, 11.70% of its market cap.
Total Valuation
Enterprise value is 11.70% below the market cap, as cash exceeds debt.
| Market Cap | $172.64M |
|---|---|
| Enterprise Value | $152.44M |
| Latest price (Nov 17, 2026) | $4.23 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 271.05% over 52 weeks and trades 7.03% below its 50-day average.
| Beta (1Y) | 0.60 |
|---|---|
| 52-Week Change | +271.05% |
| 1-Month Change | +25.52% |
| 3-Month Change | -29.03% |
| 6-Month Change | -7.03% |
| Total Return (1Y) | +271.05% |
| Total Return (3Y CAGR) | -36.02% |
| Return vs SPY (1Y) | +266.12% |
| Max Drawdown (1Y) | -46.34% |
| Max Drawdown (3Y) | -95.45% |
| Sharpe Ratio (1Y) | 1.19 |
| Correlation with SPY (1Y) | 0.07 |
| 50-Day Average | $4.55 |
| 200-Day Average | $4.26 |
| 52-Week Range | $1.00 to $7.19 |
| RSI (14 Days) | 48.1 |
| Average Volume (20 Days) | 254.72K |
Financial Position
Current assets cover 10.48x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 10.48x |
|---|---|
| Quick Ratio | 10.48x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -46.19% and return on assets is -42.56% over the last 12 months.
| Return on Equity (ROE) | -46.19% |
|---|---|
| Return on Assets (ROA) | -42.56% |
| ROA (5Y Average) | -46.42% |
| ROIC (5Y Average) | -45.86% |
Scores
ANTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$37.44M |
| Pretax Income | -$34.88M |
| Net Income | -$34.88M |
| Reported EPS (TTM) | -$0.93 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 92.14% of the $81.95M in total assets.
| Cash and Equivalents | $20.21M |
|---|---|
| Total Debt | $0 |
| Net Cash | $20.21M |
| Net Cash Per Share | $0.44 |
| Working Capital | $59.49M |
| Shareholder Equity | $75.51M |
| Book Value Per Share | $1.64 |
| Total Assets | $81.95M |
| Total Liabilities | $6.45M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$30.41M |
|---|---|
| FCF Per Share | -$0.81 |
| Depreciation and Amortization | $494.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -35.29% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -35.29% |
Dividends and Yields
ANTX does not pay a dividend.
| Buyback Yield | -15.35% |
|---|---|
| Shareholder Yield | -15.35% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ANTX
What is ANTX's market cap?
AN2 Therapeutics has a market cap of $172.64M. Its enterprise value, which adds debt and subtracts cash, is $152.44M.
How many shares of ANTX are outstanding?
AN2 Therapeutics has 46.11M shares outstanding. The count is up 52.31% from a year earlier.
Does ANTX pay a dividend?
No. AN2 Therapeutics does not pay a dividend.
How much debt does ANTX have?
AN2 Therapeutics has $0 of total debt and $20.21M of cash and equivalents, a net cash position of $20.21M.
ANTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts